ulcerative colitis
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (i) Ulcerative colitis patients seen between May 1, 2023 and September 30, 2025 with a pMayo score of 6 or higher (ii) Patients who are able to obtain written consent for research participation of their own free will. (iii) Patients whose age at the time of consent is between 18 and 80 years old. (iv) Gender: any gender (v) Inpatient/outpatient: any
Exclusion criteria
Exclusion criteria: (i) Women who are pregnant or may become pregnant (ii) Patients after total colorectal resection (iii) Patients whom the attending physician deems inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Predicted effect of pre-treatment mucosal gene expression levels in subjects who achieved clinical remission/non-remission (defined as pMayo score <= 2) at week 16 after remission induction treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of pre-treatment gene expression by drug and effect used in remission induction therapy Comparison of pre-treatment mucosal metabolome expression by drug and effect of drugs used in remission induction therapy | — |
Countries
Japan
Contacts
Kyoto Prefectural University of Medicine Molecular Gastroenterology and Hepatology